Ísrael - enska - Ministry of Health

abic marketing ltd, israel - treprostinil as sodium - solution for infusion - treprostinil as sodium 1 mg/ml - treprostinil - treprostinil teva is indicated for the treatment of:- primary pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue disorders.- pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Ísrael - enska - Ministry of Health

abic marketing ltd, israel - treprostinil as sodium - solution for infusion - treprostinil as sodium 10 mg/ml - treprostinil - treprostinil teva is indicated for the treatment of:- primary pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue disorders.- pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Ísrael - enska - Ministry of Health

abic marketing ltd, israel - treprostinil as sodium - solution for infusion - treprostinil as sodium 2.5 mg/ml - treprostinil - treprostinil teva is indicated for the treatment of:- primary pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue disorders.- pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Ísrael - enska - Ministry of Health

abic marketing ltd, israel - treprostinil as sodium - solution for infusion - treprostinil as sodium 5 mg/ml - treprostinil - treprostinil teva is indicated for the treatment of:- primary pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue disorders.- pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Bandaríkin - enska - NLM (National Library of Medicine)

par pharmaceutical, inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to -pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1) ]. in patients with pah requiring transition from epoprostenol, treprostinil is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental effects were seen

Bandaríkin - enska - NLM (National Library of Medicine)

sandoz inc - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)] . in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug- associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmenta

Írland - enska - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - treprostinil - solution for infusion - treprostinil

Írland - enska - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - treprostinil - solution for infusion - treprostinil

Írland - enska - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - treprostinil - solution for infusion - treprostinil

Írland - enska - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - treprostinil - solution for infusion - treprostinil